On Tuesday, Kezar Life Sciences (NASDAQ:KZR) shares maintained Buy rating from TD Cowen, despite a recent pause in a key clinical trial. The pharmaceutical company experienced a setback with the halting of dosing and enrollment in its Phase 2b trial of zeto for lupus nephritis, following serious adverse events that resulted in fatalities.
The decision to pause the trial came after the occurrence of Grade 5 fatal serious adverse events (SAEs). Kezar Life Sciences is now reviewing the safety data and considering risk mitigation strategies before announcing the future course of action for zeto's development in lupus nephritis (LN).
Despite this interruption, Kezar's Phase IIa PORTOLA study in autoimmune hepatitis (AIH) continues without any reported deaths. Results from this ongoing trial are expected to be released in the first half of 2025. While the company faces challenges with its lupus nephritis trial, the continuation of the AIH study provides a silver lining.
The firm's analyst emphasized the ongoing evaluation of the trial and the anticipation of data from the AIH study. TD Cowen's stance on Kezar Life Sciences remains positive, with the analyst reiterating a Buy rating on the company's stock. Kezar's market position is described as having a negative enterprise value, yet the recommendation to buy the stock stands firm.
In other recent news, Kezar Life Sciences has faced some challenges with its Phase 2b PALIZADE clinical trial for lupus nephritis. The trial was halted after the Independent Data Monitoring Committee observed four fatal serious adverse events in patients from the Philippines and Argentina. This decision has led to a thorough assessment of safety data and potential risk mitigation strategies by the company.
In financial updates, Kezar Life Sciences reported a second-quarter net loss of $22 million and cash reserves of $164 million, projected to last until late 2026. The company has also adjusted the timeline for its Autoimmune Hepatitis treatment data, now expected in the first half of 2025.
In the realm of clinical trials, under a licensing agreement with Everest Medicines, the first patient in China has been dosed with zeto, the drug candidate for Lupus Nephritis. Kezar has decided to discontinue the development of another drug candidate, KZR-261, to focus its resources on zeto's trials.
Following these recent developments, TD Cowen reiterated a Buy rating for Kezar Life Sciences, while Jones Trading maintained a Hold rating. These are the latest updates in the company's recent news.
InvestingPro Insights
Despite the recent clinical trial setback, Kezar Life Sciences (NASDAQ:KZR) presents a mixed financial picture according to InvestingPro data. The company's market capitalization stands at $56.41 million, reflecting its current valuation in light of recent events.
InvestingPro Tips highlight that KZR holds more cash than debt on its balance sheet, which could provide some financial stability during this challenging period. This liquidity position is further supported by the fact that the company's liquid assets exceed short-term obligations, potentially offering a buffer as it navigates the paused lupus nephritis trial and focuses on its ongoing autoimmune hepatitis study.
However, investors should note that KZR is quickly burning through cash and is not profitable over the last twelve months. This aligns with the article's mention of the company's negative enterprise value. The gross profit margin for the last twelve months as of Q2 2023 stands at a concerning -1040.71%, indicating significant challenges in profitability.
On a more positive note, KZR has shown strong returns over the last week (40.07%), month (28.74%), and three months (32.49%), suggesting some investor optimism despite the clinical trial pause. Analysts anticipate sales growth in the current year, which could be linked to expectations from the ongoing PORTOLA study in autoimmune hepatitis.
For those interested in a deeper analysis, InvestingPro offers 12 additional tips for KZR, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.